SKI Market

Indian Indices

Sensex

83,817.69 78.56
( 0.09%)

Global Indices

Nasdaq

49,263.38 -165.29
(-0.33%)

Dow Jones

6,939.76 -57.68
(-0.82%)

Hang Seng

54,378.12 -342.54
(-0.63%)

Nikkei 225

10,444.71 130.12
(1.26%)

Forex

USD-INR

90.33 -1.29
(-1.40%)

EUR-INR

106.65 -1.90
(-1.75%)

GBP-INR

123.60 -1.74
(-1.39%)

JPY-INR

0.58 -0.01
(-1.94%)

YOU ARE HERE :
HOME
Markets
Equity
Company News Details

EQUITY - MARKET SCREENER

Hikal Ltd

Industry : Pharmaceuticals - Indian - Bulk Drugs

BSE Code

ISIN Demat

Book Value()

524735

INE475B01022

96.8412723

NSE Symbol

P/E(TTM)

Mar.Cap( Cr.)

HIKAL

235.72

2412.38

EPS(TTM)

Face Value()

Div & Yield %

0.83

0.41

Back

Concord Biotech consolidated net profit declines 33.59% in the September 2025 quarter

Nov 15,2025

Net profit of Concord Biotech declined 33.59% to Rs 63.58 crore in the quarter ended September 2025 as against Rs 95.74 crore during the previous quarter ended September 2024. Sales declined 20.35% to Rs 247.06 crore in the quarter ended September 2025 as against Rs 310.18 crore during the previous quarter ended September 2024.

Particulars	Quarter Ended
	Sep. 2025	Sep. 2024	% Var.
Sales	247.06	310.18	-20
OPM %	35.82	43.11	-
PBDT	104.08	143.65	-28
PBT	85.68	130.34	-34
NP	63.58	95.74	-34

83,817.69 78.56 ( 0.09%)

49,263.38 -165.29 (-0.33%)

6,939.76 -57.68 (-0.82%)

54,378.12 -342.54 (-0.63%)

10,444.71 130.12 (1.26%)

90.33 -1.29 (-1.40%)

106.65 -1.90 (-1.75%)

123.60 -1.74 (-1.39%)

0.58 -0.01 (-1.94%)